Join the Ovarian Cancer group to help and get support from people like you.
Ovarian Cancer News (Page 2)
Related terms: Cancer, Ovarian, Cancer, Ovaries
Cell-Free DNA Methylation Liquid Biopsy Discriminates Ovarian Cancer
THURSDAY, Oct. 19, 2023 – A classifier based on cell-free DNA (cfDNA) methylation liquid biopsy can discriminate high-grade serous ovarian carcinoma (HGSOC) from benign masses, according to a study...
Common PFAS Chemicals Linked to Cancers in Women
TUESDAY, Sept. 19, 2023 – Harmful "forever" chemicals are widespread in the environment, and new research hints they pose a particular health risk to women. A new study suggests women who are...
Early-Life Removal of Ovaries Could Bring Faster Aging
THURSDAY, Sept. 14, 2023 – Premenopausal women who have surgery to remove the ovaries (oophorectomy) and fallopian tubes may face chronic medical conditions and a decline in physical functioning,...
Aerobic Exercise Might Ease Pain for Women Who've Survived Ovarian Cancer
WEDNESDAY, Aug. 9, 2023 – Patients being treated for ovarian cancer often experience peripheral neuropathy, a side effect from their chemotherapy that can cause both pain and numbness for months, or...
Aerobic Exercise Cuts Chemotherapy-Induced Peripheral Neuropathy Symptoms
WEDNESDAY, Aug. 2, 2023 – A six-month aerobic exercise intervention significantly improves self-reported chemotherapy-induced peripheral neuropathy (CIPN) among patients treated for ovarian cancer,...
FDA Approves Elahere (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer
Elahere is the First ADC Approved by FDA for Platinum-Resistant Ovarian Cancer Indication Covers Patients with One to Three Prior Systemic Treatment Regimens, Regardless of Prior Avastin® Use ...
FDA Approves Vegzelma (bevacizumab-adcd), a Biosimilar to Avastin
Vegzelma is Celltrion’s third oncology biosimilar to receive approval from the U.S. FDA Vegzelma offers U.S. patients living with multiple types of cancer a new, safe, and effective treatment option ...
FDA Approves Alymsys (bevacizumab-maly), a Biosimilar to Avastin
BRIDGEWATER, N.J.--(BUSINESS WIRE) April 13, 2022 --Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
FDA Approves Zejula (niraparib) as the Only Once-Daily PARP Inhibitor in First-Line Monotherapy Maintenance Treatment for Women with Platinum-Responsive Advanced Ovarian Cancer Regardless of Biomarker Status
London UK – 29 April 2020 -- Dr. Hal Barron, Chief Scientific Officer and President R&D, GSK, said: “Women with advanced ovarian cancer have a five-year survival rate of less than 50%. This expanded ...
FDA Approves Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer
23 October 2019 – GlaxoSmithKline (LSE/NYSE: GSK) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication for Zejula...
Lynparza (olaparib) Approved by US FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer
19 December 2018 – AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has approved Lynparza for use as...
FDA Approves Genentech’s Avastin (bevacizumab) Plus Chemotherapy as a Treatment for Women With Advanced Ovarian Cancer Following Initial Surgery
South San Francisco, CA – June 13, 2018 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® ...
Rubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer
BOULDER, Colo.--(BUSINESS WIRE)--Apr. 6, 2018-- Clovis Oncology, Inc. (NASDAQ:CLVS) today announced that the U.S. Food and Drug Administration (FDA) has approved Rubraca (rucaparib) tablets for the...
FDA Approves Tablet Formulation of Lynparza (olaparib) for Maintenance Treatment of Ovarian Cancer
August 17, 2017 – AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the U.S. and Canada) today announced that the US Food and Drug Administration (FDA) has granted approval for the...
Tesaro Announces FDA Approval of Zejula (niraparib) for Women with Recurrent Ovarian Cancer
WALTHAM, MA, March 27, 2017 – Tesaro, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Zejula (...
Ask a question
To post your own question to this support group, sign in or create an account.